Asset Details
Do you wish to reserve the book?
Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors
Do you wish to request the book?
Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors
2019
Overview
Proteases are a major enzyme group playing important roles in a wide variety of biological processes in life forms ranging from viruses to mammalians. The aberrant activity of proteases can lead to various diseases; consequently, host proteases have been the focus of intense investigation as potential therapeutic targets. A wide range of viruses encode proteases which play an essential role in viral replication and, therefore, constitute attractive targets for the development of antiviral therapeutics. There are numerous examples of successful drug development targeting cellular and viral proteases, including antivirals against human immunodeficiency virus and hepatitis C virus. Most FDA-approved antiviral agents are peptidomimetics and macrocyclic compounds that interact with the active site of a targeted protease. Norovirus proteases are cysteine proteases that contain a chymotrypsin-like fold in their 3D structures. This review focuses on our group’s efforts related to the development of norovirus protease inhibitors as potential anti-norovirus therapeutics. These protease inhibitors are rationally designed transition-state inhibitors encompassing dipeptidyl, tripeptidyl and macrocyclic compounds. Highly effective inhibitors validated in X-ray co-crystallization, enzyme and cell-based assays, as well as an animal model, were generated by launching an optimization campaign utilizing the initial hit compounds. A prodrug approach was also explored to improve the pharmacokinetics (PK) of the identified inhibitors.
Publisher
MDPI AG,MDPI
Subject
/ Antiviral Agents - chemistry
/ Antiviral Agents - pharmacology
/ Caliciviridae Infections - drug therapy
/ Chronic obstructive pulmonary disease
/ Diabetes
/ Enzymes
/ Genomes
/ HIV
/ Human immunodeficiency virus
/ Ischemia
/ Peptide Hydrolases - metabolism
/ Protease Inhibitors - chemistry
/ Protease Inhibitors - pharmacology
/ Proteins
/ Review
/ Virus Replication - drug effects
/ Viruses
